BIOMAT Database Logo BIOMAT Database Logo

Long-term cardiometabolic morbidity in young adults with classic 21-hydroxylase deficiency congenital adrenal hyperplasia. 2023

Beatrice Righi, and Salma R Ali, and Jillian Bryce, and Jeremy W Tomlinson, and Walter Bonfig, and Federico Baronio, and Eduardo C Costa, and Guilherme Guaragna-Filho, and Guy T'Sjoen, and Martine Cools, and Renata Markosyan, and Tania A S S Bachega, and Mirela C Miranda, and Violeta Iotova, and Henrik Falhammar, and Filippo Ceccato, and Marianna R Stancampiano, and Gianni Russo, and Eleni Daniel, and Richard J Auchus, and Richard J Ross, and S Faisal Ahmed
Developmental Endocrinology Research Group, University of Glasgow, Royal Hospital For Sick Children, Glasgow, UK. beatrice.righi2406@gmail.com.

To study the current practice for assessing comorbidity in adults with 21-hydroxylase CAH and to assess the prevalence of comorbidity in these adults. A structured questionnaire was sent to 46 expert centres managing adults with CAH. Information collected included current therapy and surveillance practice with a particular focus on osteoporosis/osteopaenia, hyperlipidaemia, type 2 diabetes/hyperinsulinaemia, hypertension, CV disease, obesity. Of the 31 (67%) centres from 15 countries that completed the survey, 30 (97%) screened for hypertension by measuring blood pressure, 30 (97%) screened for obesity, 26 (84%) screened for abnormal glucose homoeostasis mainly by using Hb1Ac (73%), 25 (81%) screened for osteoporosis mainly by DXA (92%), 20 (65%) screened for hyperlipidaemia and 6 (19%) screened for additional CV disease. Of the 31 centres, 13 provided further information on the six co-morbidities in 244 patients with a median age of 33 yrs (range 19, 94). Of these, 126 (52%) were females and 174 (71%) received fludrocortisone in addition to glucocorticoids. Of the 244 adults, 73 (30%) were treated for at least one comorbidity and 15 (21%) for more than 2 co-morbidities. Of 73, the patients who were treated for osteoporosis/osteopaenia, hyperlipidaemia, type 2 diabetes/hyperinsulinaemia, hypertension, CV disease, obesity were 43 (59%), 17 (23%), 16 (22%), 10 (14%), 8 (11), 3 (4%) respectively. Cardiometabolic and bone morbidities are not uncommon in adults with CAH. There is a need to standardise the screening for these morbidities from early adulthood and to explore optimal therapy through routine collection of standardised data.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008297 Male Males
D009765 Obesity A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
D010024 Osteoporosis Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis. Age-Related Osteoporosis,Bone Loss, Age-Related,Osteoporosis, Age-Related,Osteoporosis, Post-Traumatic,Osteoporosis, Senile,Senile Osteoporosis,Osteoporosis, Involutional,Age Related Osteoporosis,Age-Related Bone Loss,Age-Related Bone Losses,Age-Related Osteoporoses,Bone Loss, Age Related,Bone Losses, Age-Related,Osteoporoses,Osteoporoses, Age-Related,Osteoporoses, Senile,Osteoporosis, Age Related,Osteoporosis, Post Traumatic,Post-Traumatic Osteoporoses,Post-Traumatic Osteoporosis,Senile Osteoporoses
D002318 Cardiovascular Diseases Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM. Adverse Cardiac Event,Cardiac Events,Major Adverse Cardiac Events,Adverse Cardiac Events,Cardiac Event,Cardiac Event, Adverse,Cardiac Events, Adverse,Cardiovascular Disease,Disease, Cardiovascular,Event, Cardiac
D003924 Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY. Diabetes Mellitus, Adult-Onset,Diabetes Mellitus, Ketosis-Resistant,Diabetes Mellitus, Maturity-Onset,Diabetes Mellitus, Non-Insulin-Dependent,Diabetes Mellitus, Slow-Onset,Diabetes Mellitus, Stable,MODY,Maturity-Onset Diabetes Mellitus,NIDDM,Diabetes Mellitus, Non Insulin Dependent,Diabetes Mellitus, Noninsulin Dependent,Diabetes Mellitus, Noninsulin-Dependent,Diabetes Mellitus, Type II,Maturity-Onset Diabetes,Noninsulin-Dependent Diabetes Mellitus,Type 2 Diabetes,Type 2 Diabetes Mellitus,Adult-Onset Diabetes Mellitus,Diabetes Mellitus, Adult Onset,Diabetes Mellitus, Ketosis Resistant,Diabetes Mellitus, Maturity Onset,Diabetes Mellitus, Slow Onset,Diabetes, Maturity-Onset,Diabetes, Type 2,Ketosis-Resistant Diabetes Mellitus,Maturity Onset Diabetes,Maturity Onset Diabetes Mellitus,Non-Insulin-Dependent Diabetes Mellitus,Noninsulin Dependent Diabetes Mellitus,Slow-Onset Diabetes Mellitus,Stable Diabetes Mellitus
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006946 Hyperinsulinism A syndrome with excessively high INSULIN levels in the BLOOD. It may cause HYPOGLYCEMIA. Etiology of hyperinsulinism varies, including hypersecretion of a beta cell tumor (INSULINOMA); autoantibodies against insulin (INSULIN ANTIBODIES); defective insulin receptor (INSULIN RESISTANCE); or overuse of exogenous insulin or HYPOGLYCEMIC AGENTS. Compensatory Hyperinsulinemia,Endogenous Hyperinsulinism,Exogenous Hyperinsulinism,Hyperinsulinemia,Hyperinsulinemia, Compensatory,Hyperinsulinism, Endogenous,Hyperinsulinism, Exogenous
D000312 Adrenal Hyperplasia, Congenital A group of inherited disorders of the ADRENAL GLANDS, caused by enzyme defects in the synthesis of cortisol (HYDROCORTISONE) and/or ALDOSTERONE leading to accumulation of precursors for ANDROGENS. Depending on the hormone imbalance, congenital adrenal hyperplasia can be classified as salt-wasting, hypertensive, virilizing, or feminizing. Defects in STEROID 21-HYDROXYLASE; STEROID 11-BETA-HYDROXYLASE; STEROID 17-ALPHA-HYDROXYLASE; 3-beta-hydroxysteroid dehydrogenase (3-HYDROXYSTEROID DEHYDROGENASES); TESTOSTERONE 5-ALPHA-REDUCTASE; or steroidogenic acute regulatory protein; among others, underlie these disorders. Congenital Adrenal Hyperplasia,Hyperplasia, Congenital Adrenal,Adrenal Hyperplasias, Congenital,Congenital Adrenal Hyperplasias,Hyperplasias, Congenital Adrenal

Related Publications

Beatrice Righi, and Salma R Ali, and Jillian Bryce, and Jeremy W Tomlinson, and Walter Bonfig, and Federico Baronio, and Eduardo C Costa, and Guilherme Guaragna-Filho, and Guy T'Sjoen, and Martine Cools, and Renata Markosyan, and Tania A S S Bachega, and Mirela C Miranda, and Violeta Iotova, and Henrik Falhammar, and Filippo Ceccato, and Marianna R Stancampiano, and Gianni Russo, and Eleni Daniel, and Richard J Auchus, and Richard J Ross, and S Faisal Ahmed
Long-Term Health Outcomes of Korean Adults With Classic Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency.
January 2021, Frontiers in endocrinology,
Beatrice Righi, and Salma R Ali, and Jillian Bryce, and Jeremy W Tomlinson, and Walter Bonfig, and Federico Baronio, and Eduardo C Costa, and Guilherme Guaragna-Filho, and Guy T'Sjoen, and Martine Cools, and Renata Markosyan, and Tania A S S Bachega, and Mirela C Miranda, and Violeta Iotova, and Henrik Falhammar, and Filippo Ceccato, and Marianna R Stancampiano, and Gianni Russo, and Eleni Daniel, and Richard J Auchus, and Richard J Ross, and S Faisal Ahmed
Long-term Consequences of Congenital Adrenal Hyperplasia due to Classic 21-hydroxylase Deficiency in Adolescents and Adults.
March 2017, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association,
Beatrice Righi, and Salma R Ali, and Jillian Bryce, and Jeremy W Tomlinson, and Walter Bonfig, and Federico Baronio, and Eduardo C Costa, and Guilherme Guaragna-Filho, and Guy T'Sjoen, and Martine Cools, and Renata Markosyan, and Tania A S S Bachega, and Mirela C Miranda, and Violeta Iotova, and Henrik Falhammar, and Filippo Ceccato, and Marianna R Stancampiano, and Gianni Russo, and Eleni Daniel, and Richard J Auchus, and Richard J Ross, and S Faisal Ahmed
21-hydroxylase deficiency congenital adrenal hyperplasia.
January 1994, The Journal of steroid biochemistry and molecular biology,
Beatrice Righi, and Salma R Ali, and Jillian Bryce, and Jeremy W Tomlinson, and Walter Bonfig, and Federico Baronio, and Eduardo C Costa, and Guilherme Guaragna-Filho, and Guy T'Sjoen, and Martine Cools, and Renata Markosyan, and Tania A S S Bachega, and Mirela C Miranda, and Violeta Iotova, and Henrik Falhammar, and Filippo Ceccato, and Marianna R Stancampiano, and Gianni Russo, and Eleni Daniel, and Richard J Auchus, and Richard J Ross, and S Faisal Ahmed
21-hydroxylase deficiency congenital adrenal hyperplasia.
January 2010, Neonatal network : NN,
Beatrice Righi, and Salma R Ali, and Jillian Bryce, and Jeremy W Tomlinson, and Walter Bonfig, and Federico Baronio, and Eduardo C Costa, and Guilherme Guaragna-Filho, and Guy T'Sjoen, and Martine Cools, and Renata Markosyan, and Tania A S S Bachega, and Mirela C Miranda, and Violeta Iotova, and Henrik Falhammar, and Filippo Ceccato, and Marianna R Stancampiano, and Gianni Russo, and Eleni Daniel, and Richard J Auchus, and Richard J Ross, and S Faisal Ahmed
Growth in patients with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
January 2007, Hormone research,
Beatrice Righi, and Salma R Ali, and Jillian Bryce, and Jeremy W Tomlinson, and Walter Bonfig, and Federico Baronio, and Eduardo C Costa, and Guilherme Guaragna-Filho, and Guy T'Sjoen, and Martine Cools, and Renata Markosyan, and Tania A S S Bachega, and Mirela C Miranda, and Violeta Iotova, and Henrik Falhammar, and Filippo Ceccato, and Marianna R Stancampiano, and Gianni Russo, and Eleni Daniel, and Richard J Auchus, and Richard J Ross, and S Faisal Ahmed
Long-term outcome of patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
November 2012, The American journal of the medical sciences,
Beatrice Righi, and Salma R Ali, and Jillian Bryce, and Jeremy W Tomlinson, and Walter Bonfig, and Federico Baronio, and Eduardo C Costa, and Guilherme Guaragna-Filho, and Guy T'Sjoen, and Martine Cools, and Renata Markosyan, and Tania A S S Bachega, and Mirela C Miranda, and Violeta Iotova, and Henrik Falhammar, and Filippo Ceccato, and Marianna R Stancampiano, and Gianni Russo, and Eleni Daniel, and Richard J Auchus, and Richard J Ross, and S Faisal Ahmed
Long-term outcome of patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
January 2007, Hormone research,
Beatrice Righi, and Salma R Ali, and Jillian Bryce, and Jeremy W Tomlinson, and Walter Bonfig, and Federico Baronio, and Eduardo C Costa, and Guilherme Guaragna-Filho, and Guy T'Sjoen, and Martine Cools, and Renata Markosyan, and Tania A S S Bachega, and Mirela C Miranda, and Violeta Iotova, and Henrik Falhammar, and Filippo Ceccato, and Marianna R Stancampiano, and Gianni Russo, and Eleni Daniel, and Richard J Auchus, and Richard J Ross, and S Faisal Ahmed
Steroid 21 hydroxylase deficiency congenital adrenal hyperplasia.
October 2011, Pediatric clinics of North America,
Beatrice Righi, and Salma R Ali, and Jillian Bryce, and Jeremy W Tomlinson, and Walter Bonfig, and Federico Baronio, and Eduardo C Costa, and Guilherme Guaragna-Filho, and Guy T'Sjoen, and Martine Cools, and Renata Markosyan, and Tania A S S Bachega, and Mirela C Miranda, and Violeta Iotova, and Henrik Falhammar, and Filippo Ceccato, and Marianna R Stancampiano, and Gianni Russo, and Eleni Daniel, and Richard J Auchus, and Richard J Ross, and S Faisal Ahmed
Steroid 21 hydroxylase deficiency congenital adrenal hyperplasia.
December 2009, Endocrinology and metabolism clinics of North America,
Beatrice Righi, and Salma R Ali, and Jillian Bryce, and Jeremy W Tomlinson, and Walter Bonfig, and Federico Baronio, and Eduardo C Costa, and Guilherme Guaragna-Filho, and Guy T'Sjoen, and Martine Cools, and Renata Markosyan, and Tania A S S Bachega, and Mirela C Miranda, and Violeta Iotova, and Henrik Falhammar, and Filippo Ceccato, and Marianna R Stancampiano, and Gianni Russo, and Eleni Daniel, and Richard J Auchus, and Richard J Ross, and S Faisal Ahmed
[Steroid 21-hydroxylase deficiency--congenital adrenal hyperplasia].
April 1988, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme,
Copied contents to your clipboard!